Type 2 Inflammation Biologic (Anti-IL-5) from GlaxoSmithKline (GSK).
Exdensur is a long-acting IL-5 monoclonal antibody dosed twice yearly (every 6 months) for severe eosinophilic asthma. The twice-yearly dosing interval is a meaningful convenience change compared to the every-4-week and every-8-week dosing of other IL-5 pathway biologics. It is FDA-approved as add-on maintenance treatment in patients 12 years and older with severe asthma and an eosinophilic phenotype.
Exdensur is FDA-approved for the following indications:
Note on nasal polyps: Depemokimab has been approved for chronic rhinosinusitis with nasal polyps in the EU and UK, but that indication is still under FDA review in the United States. In the US, Exdensur is currently approved for severe eosinophilic asthma only.
Exdensur is administered subcutaneously every six months, typically as an in-office injection.
The manufacturer offers a patient support program — GSK For You Patient Assistance — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.gskforyou.com.
Treatment with Exdensur is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. This is a subcutaneous self-administered medication. After prior authorization, the prescription is sent to a specialty pharmacy that ships the medication directly to the patient. A manufacturer-sponsored nurse or office-based training visit is typically arranged for the first dose so patients are confident with self-administration before continuing at home.
A note on age: The FDA indications above may include pediatric or adolescent age groups. Optimed Immunology's clinical practice is focused on adults. If you are seeking care for a minor, please contact the office and we can advise on referral options.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.exdensur.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Exdensur is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.